Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor. Due to its rarity no appropriate treatment protocol is made so far. Here we report a case treated with neoadjuvant chemotherapy followed by radiation therapy in an old debilitated patient. At three months follow-up, clinically no residual and recurrence of disease is noted.
Merkel cell carcinoma was first described by Toker. 1 This rare skin tumor is also known by various names such as primary small cell carcinoma of skin, primary neuroendocrine carcinoma of skin, primary undifferentiated carcinoma of skin, anaplastic carcinoma of skin, trabecular carcinoma of skin, and cutaneous amine precursor uptake and decarboxylation tumor APUDoma. 2 The tumor arises from neurocrest derivative merkel cell of epidermis situated in the basal layer which contains neuro-secretory granules. The early lesion is often asymptomatic and may present as firm glossy, non-tender, bluish-red or bluishpurple, rapidly growing nodule at the time of presentation. 2, 3 There are a few reported cases of merkel cell carcinoma so far and to the best of our knowledge this case report is the first in North-East India.
Case Illustration
A 87 year-old male was admitted to hospital with complaint of a painless ulcer measuring 6 x 6 cm located over skin of right upper outer quadrant of buttock. Unlike decubitous ulcer, the ulcer was rapidly proliferative, with reddish thickened, everted margin, violaceous hue around the ulcer for the last two months. The patient has no history of smoking, alcohol consumption, and chewing tobacco. On general physical and systemic examinations revealed no abnormality.
All routine investigation such as complete haemogram, kidney and liver function test, random blood sugar level was within normal limit, his chest X-ray, ultrasonography (USG) whole abdomen and screening bilateral inguinal lymphnodes showed no lymphadenopathy. His performance status was 40% (Karnofsky scale). In view of clinically suspicious malignant ulcer, biopsy was done and reported small cell carcinoma with numerous mitotic figures and suggesting MCC. Further, immunohistochemical status of cytokeratin (CK)7 and CK20 were investigated and found CK20 positive and CK7 negative. On the basis of clinical, imaging, histopathologic and tissue immunohistochemistry findings, the case was diagnosed as MCC; stage IIB tumor, node, metastasis (TNM) staging, T3cNoMo. Patient was explained of about different treatment modalities with their pros and cons and patient opted chemotherapy and radiation therapy.
Patient received neo-adjuvant chemotherapy (NACT) injection carboplatin 420 mg (day one) and etoposide 140 mg (day one to three), three weekly for three cycles followed conventional fractionation external beam radiotherapy giving up to a total dose of 60 Gy, 200cGy/fraction over six weeks by medial and lateral tangential fields with Cobalt 60 machine. One month following treatment, there was no residual disease clinically and patient was kept under follow-up. He was disease-free at his last check-up three months after completion of treatment. 
DISCUSSION
Merkel cell carcinoma is an uncommon, highly malignant neuroendocrine cutaneous tumor with overall unfavorable prognosis. 4 The tumor is generally seen in sun exposed areas such as head and neck (50%), extremities (35-40%), and upper body but less than 10% cases appear in the trunk of fair elderly men. 5 A rare site like pharynx, an oral or nasal mucosa, vulva, and penile may also be involved. 6 Although the exact etiology is not fully understood, there are several risk factors that contribute to its pathogenesis such as ultraviolet (UV) light, sun exposure related skin malignancy, and treatment with methoxsalen. Elderly and immunocompromised patients prone to develop MCC. Polyoma virus is incriminated as one of the causative agents. [4] [5] [6] [7] [8] Clinically MCC may present as a non-tender, firm, painless nodule, sometimes with ulcerated skin lesion with a reddish or violaceous hue less than 2 cm at presentation. [8] [9] [10] Because of the low incidence rate and asymptomatic in its early clinical course, diagnosis is often delayed, or even missed. Around 70-80% of MCC present as localized disease, 9-26% as invasion of regional lymph nodes and 1-4% extra-nodal distant metastasis. Histologically, MCC looks small round blue cells, with scanty cytoplasm, hyperchromatic nuclei, multiple nucleoli, delicately granular chromatin, abundant mitoses, and numerous apoptotic figures. 5 Diagnosis of MCC is usually confirmed by clinical, histopathologic, and immunohistochemistry reports of the tissue biopsy. The differential diagnosis to be made between MCC from other tumors is small cell lung cancer, cutaneous lymphoma, amelanotic melanoma, and other primitive neuroendocrine tumor (PNET) category.
11 MCC is CK20 positive and expressed characteristic paranuclear dot pattern. MCC is neuron specific enolase positive, S-100 (soluble-100, protein) weak positive and stain for cluster of differentiation CD117 .
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Merkel cell carcinoma is a rapidly growing tumor. Nearly one-third of patients die within three years from the time of diagnosis. 12 Unfavorable prognostic factors include male gender, age more than 65 years with co-morbid diseases, distant metastatic disease, tumor of head and neck region, tumor size more than 2 cm in diameter, tumor with more than 10 mitoses per high-power field, evidence of vascular invasion, absence of an inflammatory reaction, and high expression of Kiel (Ki)-67 (proliferation index marker). 4, 13 Lymph node involvement decreases survival from 88% to 50% and it shows within two years in 50% to 70% of all patients. MCC is a rapidly progressive fatal disease. Considering the high local recurrence 27-60%, regional involvement 45-91% or distant metastasis 18%-52% patients should be closely followed up after definitive treatment. 5, 14 The rareness of the disease and the lack of prospective clinical studies evaluating the efficacy of therapeutic options, caused limited set of treatment guidelines. 5 Surgery is the mainstay of treatment and remains the gold standard for localized disease. Surgery alone has very high local recurrence rates for this disease. 12, 13 Wide surgical resection taking http://mji.ui.ac.id 3 cm margin and 2.5 cm dept is sufficient, but some authors advocate less than 2-3 cm in case of 1.5-2 cm tumor without high local recurrence. An alternative to wide local resection is Mohs micrographic surgery. 15 Surgical dissection of all lymph nodes is controversial, many authors advocate complete lymph node dissection in case of positive lymph node at presentation. 5 One study recommended prophylactic lymphadenectomy only if the lesion is more than six weeks and tumor more than 1.5 cm in size prior to seeking medical advice and sentinel lymph node biopsy in case of negative node. 16 On the contrary, prophylactic lymphadenectomy is neither recommended as a standard management scheme nor in sentinel lymph node (SLN)-negative biopsies; however, it is recommended in MCC with increased risk of potential recurrence and aggressive metastasis. 17 Merkel cell carcinoma is predominantly a radiosensitive malignancy. Surgery alone has very high local recurrence rates for this disease. Postoperative radiotherapy increases survival than surgery alone. Radiotherapy plays an important role in case of large primary tumor or unattainable free surgical margin due to cosmetic or surgical difficulties and increases overall survival. 12, 13, 18 In case of metastatic disease, treatment option consists of palliative radiotherapy and chemotherapy. MCC is also a chemo-sensitive tumor. Tumur regression and remission rates can be as high as 70% with chemotherapy, however without significant prolonged survival benefit.
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Multiple agents have been used with different response rates.
14 Those include cyclophosphamide, doxorubicin, etoposide, cisplatin, vincristine, methotrexate, fluorouracil (FU), carboplatin, etc. 5, 12 Biologic agents like anti-tumor necrosis factor and imatinib mesylate promises better result on local or systemic control of MCC. 6 Radiotherapy can be used in case of cutaneous deposits or bone and brain metastasis. 5 In conclusion, MCC is a very rare skin cancer. The incidence of MCC may be increasing in future in modern society due to increase life span. Thus, there is paramount importance of awareness among clinicians about the possibility of MCC in elderly patients. There is high need for routine skin biopsy for any painless, nontender, proliferative, with reddish thickening margin, violaceous hue around the ulcer, and rapidly growing skin nodule to rule out MCC prior to any treatment is being suggested in this disease.
